Is tirzepatide safe for people with type 2 diabetes?

Several trials in this review included people with type 2 diabetes, and tirzepatide showed no significant increase in serious side effects or heart/stroke events. However, all trials were funded by the manufacturer. Always consult your diabetes care team before starting or changing any medication.

What side effects should I watch out for with tirzepatide?

The most common side effects are non-serious digestive issues such as nausea, vomiting, and diarrhea, which were more frequent in the tirzepatide group. Serious side effects occurred at similar rates to placebo. Tell your doctor if side effects are severe or persistent.

Does the weight loss last long-term?

One study followed participants for 3.5 years and found that weight loss was maintained at around 15–16% reduction. However, evidence on long-term outcomes beyond that period is still limited, and more independent research is needed.

Tirzepatide for Obesity: 16% Weight Loss in Major Review

Key takeaways

✓Average weight loss of ~16% of body weight compared to placebo over 12–18 months
✓Weight loss was sustained at 3.5 years of follow-up in longer-term data
✓No significant increase in serious adverse events, heart attacks, strokes, or death rates compared to placebo
✓Participants were 3.6 times more likely to achieve the clinically meaningful 5% weight loss threshold

Quick specs

Journal	The Cochrane database of systematic reviews
Year	2025
PMID	41161687

What Was This Study About?

Researchers reviewed 9 clinical trials involving 7,111 adults living with obesity to understand how well tirzepatide (brand name Mounjaro) works for weight loss. Tirzepatide is a weekly injection that targets two hormones — GIP and GLP-1 — to help control appetite and blood sugar.

What Did They Find?

Compared to placebo (a dummy injection), people taking tirzepatide lost an average of about 16% of their body weight over 12–18 months. For someone weighing 250 lbs, that's roughly 40 lbs of weight loss. People taking tirzepatide were also 3.6 times more likely to lose at least 5% of their body weight — a meaningful health threshold.

Importantly, this weight loss appeared to be sustained at 3.5 years in longer follow-up data, with participants maintaining around 15–16% weight reduction.

What About Safety?

Tirzepatide did increase non-serious side effects (like nausea or digestive issues) compared to placebo. However, serious side effects were similar between tirzepatide and placebo groups. There was no meaningful difference in heart attack/stroke risk (MACE) or death rates between the groups.

What About Quality of Life?

Physical quality of life scores improved slightly with tirzepatide, but researchers noted the difference may not be clinically dramatic in everyday terms.

Important Caveats

All 9 studies were funded by the drug manufacturer (Eli Lilly), which raises concerns about potential bias. Most trials focused on middle- and high-income countries, so results may not apply to all populations. Independent research is still needed.

What This Means for Diabetes Patients

Several of the trials specifically included people with type 2 diabetes or prediabetes. For these patients, meaningful weight loss from tirzepatide could help improve blood sugar control, reduce cardiovascular risk, and potentially reduce medication needs — though always discuss changes with your care team.

References & Sources

Frequently asked questions

In clinical trials, people on tirzepatide lost an average of about 16% of their starting body weight over 12–18 months. For a 250 lb person, that's roughly 40 lbs. Results vary by individual, and it works best alongside healthy eating and exercise.

Editorial note

This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management. Last reviewed: July 16, 2026 by the MDS Diabetes editorial team.

What to do next

📚

Tirzepatide Causes Major Weight Loss in Adults with Obesity